3 Stocks That Could Surge In Q3! Randgold Resources Limited, GlaxoSmithKline plc and British American Tobacco plc

Royston Wild considers the share price prospects of Randgold Resources Limited (LON: RRS), GlaxoSmithKline plc (LON: GSK) and British American Tobacco plc (LON: BATS).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’ve been sceptical over the durability of rocketing gold prices in 2016, and with it the share price gains enjoyed by the likes of Randgold Resources (LSE: RRS).

The yellow metal has been driven skywards mainly by a decline in the value of the US dollar — a factor that makes greenback-denominated commodities cheaper to buy — rather than by robust underlying demand.

But last week’s Brexit vote has changed the game as investors fret over the political vacuum created by David Cameron’s resignation, over a protracted withdrawal process from the EU, and the long-term impacts of a UK exit on global economic growth.

These factors pushed the ‘safe-haven’ metal to its loftiest since July 2014, above $1,320 per ounce yesterday, dragging Randgold Resources to fresh record highs of above £80 per share. And I believe gold prices could receive further fuel given the muddy political and economic outlook.

While recent share price rises leaves the gold digger dealing on a hefty P/E rating of 33.4 times, I believe the scale of market nervousness could keep sending Randgold Resources higher.

Pharma star

The pharmaceuticals sector’s giants like GlaxoSmithKline (LSE: GSK) have proved more immune to the jitters washing out the markets in recent days. And this comes as little surprise to me.

Regardless of the wider economic climate, people still need drugs and other medical treatments to stave off the reaper and treat a variety of ailments. And this makes GlaxoSmithKline a classic defensive play for many investors.

It could be argued that the ‘lumpy’ nature of drugs R&D undermines this line of thought, however. Indeed, GlaxoSmithKline is no stranger to testing setbacks that have resulted in higher developments costs, not to mention many lost millions in product delays and cancellations.

But on the whole, it has a great track record in the R&D stakes. And with the firm doubling-down on organic investment and acquisitions to bolster its product pipeline, I expect the Brentford business to deliver robust shareholder returns in the years ahead.

And I reckon a forward P/E rating of 15.6 times is a great level at which to tap into the pharma play’s hot growth potential.

Smoking share prices

Tobacco’s reputation as a go-to destination for frightened investors has come to the fore yet again, and British American Tobacco (LSE: BATS) has risen to all-time highs around £45.60 per share just this week.

The evergreen appeal of cigarette stocks is one of the surefire certainties in increasingly-turbulent times, and is a factor that should keep sending British American Tobacco’s share price higher.

And even though aggregate industry volumes are falling as health concerns weigh, British American Tobacco is able to bat away the worst of these problems through colossal brands like Lucky Strike.

Such labels are keeping earnings ticking higher through market share grabs, while their enduring popularity with smokers the world over allows British American Tobacco to hike prices regardless of wider pressures on buyers’ purses. And I expect heavy investment in these products to keep driving the bottom line.

I therefore reckon British American Tobacco remains a great stock pick irrespective of a slightly-heady forward P/E rating of 17.7 times.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »